AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03393806 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Commercially sourced sterile normal saline will be provided as Placebo
Study NCT02686645 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota
Description: The fecal microbiota will be by retention enema administered through a rectal tube.
Study NCT02686645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vancomycin
Description: All subjects will be pre-treated with vancomycin 125 mg po qid X 7 days prior to the fecal microbiota.
Study NCT02686645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide
Description: The subject will take 4 mg of loperamide after the morning bowel prep (approximately 1 hour prior to the procedure) and 2 mg again after the procedure.
Study NCT02686645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metronidazole
Description: If unable to tolerate vancomycin, then it will be substituted with metronidazole 500 mg po tid X 7 days prior to the fecal microbiota.
Study NCT02567643 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Study NCT05332028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine
Description: Block applications
Study NCT05332028 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine
Description: Block applications
Study NCT05332028 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 22 gauge 100 mm needle
Description: Block applications
Study NCT05332028 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 22 gauge 100 mm needle
Description: Block applications
Study NCT05332028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Routine general anesthesia protocol
Study NCT05332028 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Routine general anesthesia protocol
Study NCT05332028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fentanyl
Description: patient-controlled analgesia
Study NCT05332028 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl
Description: patient-controlled analgesia
Study NCT01806506 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy
Description: Laparoscopic sleeve gastrectomy (LSG) is a restrictive bariatric procedure. LSG involves resection of a large part of the body and fundus of the stomach starting from the antrum up to the angle of His. The remaining part of the stomach (the gastric sleeve) is calibrated with a 36 French bougie.
Study NCT01806506 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Roux-en-Y Gastric Bypass
Description: Roux-en-Y gastric bypass (RYGB) is an intermediate (restrictive and malabsorptive) operation. RYGB involves creation of a 15-20 mL gastric pouch that is anastomosed to a 100cm Roux limb created at 100cm from the ligament of Treitz.
Study NCT01453452 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise intervention
Description: 150 min/wk of moderate exercise through use of the Curves® centers, engage in physical activity outside of Curves®, and use pedometers to track activity.
Study NCT01453452 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: counseling intervention
Description: 14 40-min behavioral counseling sessions via telephone with the goal of increasing intervention adherence and increasing participant retention.
Study NCT01453452 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: PROMIS-43 - online questionnaire to assess quality of life.
Study NCT04221503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib (\[3S\]-3-\[4-{7-(aminocarbonyl)-2H-indazol-2-yl} phenyl\] piperidine \[tosylate monohydrate salt\]) is an orally available, potent, highly selective poly (adenosine diphosphate \[ADP\]-ribose) polymerase (PARP) -1 and -2 inhibitor. The niraparib drug product is provided as 100-mg capsules filled with a dry blend of niraparib tosylate monohydrate, lactose monohydrate, and magnesium stearate in a hard gelatin capsule.
Study NCT04221503 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niraparib
Description: Niraparib (\[3S\]-3-\[4-{7-(aminocarbonyl)-2H-indazol-2-yl} phenyl\] piperidine \[tosylate monohydrate salt\]) is an orally available, potent, highly selective poly (adenosine diphosphate \[ADP\]-ribose) polymerase (PARP) -1 and -2 inhibitor. The niraparib drug product is provided as 100-mg capsules filled with a dry blend of niraparib tosylate monohydrate, lactose monohydrate, and magnesium stearate in a hard gelatin capsule.
Study NCT04221503 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optune
Description: Optune, which is manufactured by Novocure, is a portable battery or power supply operated device which produces alternating electrical fields, called tumor treatment fields (TTFields) within the human body. TTFields are applied to the patient by electrically-insulated surface transducer arrays. TTFields disrupt the rapid cell division exhibited by cancer cells.
Study NCT04221503 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optune
Description: Optune, which is manufactured by Novocure, is a portable battery or power supply operated device which produces alternating electrical fields, called tumor treatment fields (TTFields) within the human body. TTFields are applied to the patient by electrically-insulated surface transducer arrays. TTFields disrupt the rapid cell division exhibited by cancer cells.
Study NCT04221503 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Planned surgical resection
Description: Surgery of supratentorial glioblastoma (GBM).
Study NCT04164433 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oral HIV Self-Test (OraQuick)
Description: The oral HIV self-test is a device for taking a test which is painless. The user gently swipes the test swab along the upper gums once and the lower gums once. The swab is then inserted inside the test tube provided and results are ready in 20 minutes.
Study NCT01766297 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Radiotherapy
Study NCT01823107 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Meso BioMatrix Device
Study NCT02507661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: preservation of alveolar ridge with beta tricalcium phosphate + collagen - 2 months
Study NCT02507661 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: no-preservation of alveolar ridge - 2 months
Study NCT02507661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: preservation of alveolar ridge with beta tricalcium phosphate + collagen - 4 months
Study NCT02507661 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: no-preservation of alveolar ridge - 4 months
Study NCT02507661 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: preservation of alveolar ridge with beta tricalcium phosphate + collagen - 9 months
Study NCT02507661 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: no-preservation of alveolar ridge - 9 months
Study NCT00129090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-CHOEP 14 with 12x Rituximab
Description: after amendment 3 patients receive 4x 375mg/m2 in cycle 1 (day 0,1,4,8), 2x 375/m2 in cycle 2 (day1,8) and 1x 375mg/m2 cycle 3-8 (day 1 of each cycle)
Study NCT04091932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Monthly usage of Pembrolizumab (2mg/kg weight) for 3 months.
Study NCT01325051 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Raltegravir
Description: 400 mg tablets by mouth BID from Day 1 - Day 7 after enrollment visit
Study NCT01626586 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Therapy
Description: Self-management Diabetes Protocol: Successful adjustment to daily diabetes management requires a wealth of clinical knowledge, solid problem-solving and coping skills to deal with the physical, social and emotional factors associated with caring for and living with a chronic illness, and motivation to take care of one's health.
Study NCT01626586 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Therapy
Description: Self-management Diabetes Protocol: Successful adjustment to daily diabetes management requires a wealth of clinical knowledge, solid problem-solving and coping skills to deal with the physical, social and emotional factors associated with caring for and living with a chronic illness, and motivation to take care of one's health.
Study NCT03284983 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Suture spacing for wound closure
Description: The wound was divided in half and sutures were spaced 5mm or 10mm apart depending on side. The sutures were removed at 2-week follow-up appointment and photographs were taken. The Patient and Observer Scar Assessment Scale (POSAS) was then performed by both patient and physician.
Study NCT03585725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin is FDA-approved oral medication for antiviral indications. Ribavirin will be obtained commercially for this trial.~Treatment will be administered on an outpatient basis. Ribavirin should be administered with food.
Study NCT01279044 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Adapted Personalized Cognitive Risk-reduction Counseling intervention (PCC)
Description: The individualized, cognitive counseling intervention was designed to help participants address the self-justifications-beliefs, thoughts, and attitudes-that they employed in the setting of high-risk sexual behavior, in the company of an empathic counselor.
Study NCT01279044 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard HIV testing with information only
Description: Standard HIV testing with information only
Study NCT02468440 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ESPAIR
Description: ESPAIR is an educational therapy's program with 6 group session,and if patients ask for it, individual session are possible
Study NCT04887727 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Crystalline amino acids to assess myofibrillar protein synthesis rates
Description: Amino acid dose = 0.25g/kg bodyweight
Study NCT04887727 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Crystalline amino acids to assess whole-body protein turnover, amino acid oxidation, and net protein balance
Description: Amino acid dose = 0.25g/kg bodyweight
Study NCT04294459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab SAR650984
Description: Pharmaceutical form: Solution for infusion~Route of administration: Intravenous
Study NCT04294459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen (paracetamol) or equivalent
Description: Pharmaceutical form: Tablets~Route of administration: Oral
Study NCT03720327 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Get FIT
Description: The Get FIT arm includes use of a free commercially available smartphone application to track daily food intake for 3 months; use of a Fitbit activity tracker for 3 months; and one 45 minute behavioral counseling session to set personal goals and provide education by a health coach.
Study NCT03720327 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Get FIT+
Description: The Get FIT+ arm includes use of a free commercially available smartphone application to track daily food intake for 3 months; use of a Fitbit activity tracker for 3 months; one 45 minute behavioral counseling session to set personal goals and provide education by a health coach; and personalized text messaging for 3 months by a health coach. The health coach will have access to these participants' daily food and activity data through the smartphone application, and will monitor progress and send push-only text messages to participants in this group based on the participant's goals and progress in the areas of physical activity, nutrition, and weight loss.
Study NCT04294459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranitidine or equivalent
Description: Pharmaceutical form: Solution~Route of administration: Intravenous
Study NCT04294459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine or equivalent
Description: Pharmaceutical form: Solution~Route of administration: Intravenous
Study NCT04553458 — intervention group
Intervention type: DRUG
Intervention: Symptomatic treatment
Description: Symptomatic treatment
Study NCT03085394 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tranexamic acid
Description: Preoperative intravenous administration of 2 grams tranexamic acid in 10 ml saline
Study NCT01207284 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: strengthening passive and active stretching balance training gait training
Study NCT03085394 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Preoperative intravenous administration of 10 ml saline
Study NCT00220740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified
Description: 2 g/kg body weight ideally over 2-4 days . Thereafter, study drug infusion (IGIV-C) will be administered every 3 weeks at a dose of 1 g/kg bw, given over 1-2 days for a total of 7 additional infusions
Study NCT00220740 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albumin (Human) 25%, United States Pharmacopeia (USP)
Description: Albumin 25%, USP diluted with dextrose 5% to a final concentration of 0.1% as an intravenous infusion. Alternatively, it may be a bottled placebo of 0.1% Albumin (Human) in 0.2 M Glycine, 1.1 mm sodium caprylate, 0.25% sodium chloride. 2 g/kg body weight ideally over 2-4 days . Thereafter, infusion (placebo) will be administered every 3 weeks at a dose of 1 g/kg bw, given over 1-2 days for a total of 7 additional infusions
Study NCT03257644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib phosphate cream
Description: Ruxolitinib phosphate cream at the protocol-defined dose strength based on cohort assignment.
Study NCT00692042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1704
Description: One dose, by mouth
Study NCT02590432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide
Description: Linaclotide capsules, orally, once daily.
Study NCT04294459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone or equivalent
Description: Pharmaceutical form: Solution~Route of administration: Intravenous
Study NCT04294459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast or equivalent
Description: Pharmaceutical form: Tablets~Route of administration: Oral
Study NCT02479958 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rubber dam isolation
Description: Tooth was isolated using a rubber dam isolation in order to collect the dentin samples
Study NCT02479958 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth drying
Description: The tooth was dried with air jet.
Study NCT01003613 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranilast, and Tissucol
Description: 1.0%, 0.1 ml, subconjunctival route, single dose
Study NCT01003613 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Beriplast P
Description: 0.1 ml to attach graft
Study NCT02479958 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dentin wash with chlorhexidine 2%
Description: Partial carious tissue was removed with conventional dentinal curette and collection of dentin with a micropunch (Ø = 1mm) was performed. The remaining dentin was washed with chlorhexidine 2%. After that a a new dentin collection was performed at another site of the cavity, and restoration with resin-modified glass ionomer cement was placed.
Study NCT02479958 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Antimicrobial Photodynamic Therapy 1
Description: Partial carious tissue was removed with conventional dentine curette and collection of dentin with a micropunch (Ø = 1mm) was performed. The remaining dentin was washed with 200 µL of O-Toluidine blue dye (0.1 mg/mL) for 60 s. After this, a red LED light source with wavelength of 630 nm was used at 100 mW power, 9.0 J of energy, for 60 s with energy density of 30.0 J/cm2 . A new dentin collection was performed after this treatment at another site of the cavity and restoration with resin-modified glass ionomer cement Vitremer was placed.
Study NCT02479958 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Antimicrobial Photodynamic Therapy 2
Description: Partial carious tissue was removed with conventional dentine curette and initial collection of dentin with a micropunch (Ø = 1mm) was performed. Treatment of the remaining dentin was performed with 200 µL of methylene blue dye 0.01% for 5 min and after this, a red low level LASER light source with wavelength of 660 nm was used at 100 mW power, 9.0 J of energy, for 90 s with energy density of 320.0 J/cm2 . A new dentin collection was performed after this treatment at another site of the cavity and restoration with resin-modified glass ionomer cement was placed.
Study NCT01607762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Type= exact number, unit= mg, number= 5, form= tablet, route= oral administration. A single oral dose of a 5-mg aripiprazole tablet will be administered after an overnight fast.
Study NCT01607762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: Type= exact number, unit= mg, number= 100, form= tablet, route= oral administration. A single oral dose of two 50-mg quetiapine tablets will be administered after an overnight fast.
Study NCT01607762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Type= exact number, unit= mg, number= 5, form= tablet, route= oral administration. A single oral dose of a 5-mg olanzapine tablet will be administered after an overnight fast.
Study NCT00895778 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular blockade with rocuronium and reversal with sugammadex
Study NCT00895778 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Neuromuscular blockade with rocuronium and reversal with sugammadex
Study NCT01911078 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: EnligHTN™ Renal Denervation System.
Study NCT03445715 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ART-I02
Description: Single Intra-articular injection in the wrist joint
Study NCT01267344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine, oxaliplatin
Description: GEMOX (intravenous infusion of gemcitabine 800 mg/m2 at a fixed rate of 10 mg/m2/min followed by oxaliplatin 85 mg/m2 2-hour infusion, every 2 weeks
Study NCT01267344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab, gemcitabine, oxaliplatin
Description: E-GEMOX: intravenous infusion of cetuximab (120 minutes for the 1st, 90 minutes for the 2nd and 60 minutes for all subsequent infusions) before GEMOX will be administered as above. All of the study medication will be administrated on day 1 every 2 weeks, which is regarded as one cycle.
Study NCT01204307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel/cisplatin
Description: The treatment schedule comprises a maximum of six 3-week treatment cycles consisting of weekly docetaxel (30 mg/m2) and cisplatin (37.5 mg/m2) for 2 consecutive weeks followed by a 1-week treatment-free period. The patients will be assessed after each cycle and a final assessment will be done after three and six cycles.
Study NCT01204307 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed/cisplatin
Description: The patients are given pemetrexed (500 mg/m2 as a 10-min intravenous infusion) and cisplatin (75 mg/m2) on day 1 every 21 days. Dexamethasone (4 mg) is administered twice daily on the day before, the day of, and the day after each dose of pemetrexed. Oral folic acid supplementation (1000 mg) is administered daily, beginning approximately 2 weeks prior to the first dose of pemetrexed and continues until 3 weeks after treatment discontinuation. A 1000 mg vitamin B12 injection is administered intramuscularly approximately 1-2 weeks before the first dose of pemetrexed and is repeated approximately every 9 weeks until 3 weeks after therapy discontinuation.
Study NCT05913518 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurofeedback active
Description: Neurofeedback uses real-time displays of brain activity to teach self regulation of brain function. People can learn to control their own brain activity through operant conditioning, where they receive feedback on their brainwaves and learn to modify them to achieve a desired state. Active neurofeedback group aims at enhancing the sensorimotor rhythm (12-15 Hz).
Study NCT05913518 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Neurofeedback placebo
Description: Neurofeedback uses real-time displays of brain activity to teach self regulation of brain function. People can learn to control their own brain activity through operant conditioning, where they receive feedback on their brainwaves and learn to modify them to achieve a desired state. Placebo feedback group (PFT) : patients enhance random frequency bands
Study NCT02716662 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Axona
Description: medical powder, supplement food